Outcomes and quality of life for people with vulvar and vaginal cancer treated with radiation
Official title: Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.
Run by Tata Memorial Hospital · NCT07179757 · Data updated 2026-11-12
This project will collect clinical, treatment, and quality-of-life information to see if patterns of relapse and treatment side effects can be identified in people with vulvo-vaginal cancer who receive radiation, with or without chemotherapy or surgery.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 200 (estimated) |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | chemotherapy, Radiation |
| Locations | 1 site (Mumbai, Maharashtra) |
| Status | Recruiting |
| Started | October 30, 2021 |
| Main results expected | June 30, 2026 |
| Study ends | October 1, 2026 |
| Registry record updated | February 4, 2026 |
| Trial ID | NCT07179757 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with vulvar or vaginal cancer who received radiation (with or without chemotherapy or surgery) at Tata Memorial Hospital, with retrospective records from January 1, 2019 onward and new patients enrolled prospectively after ethics approval.
✕Probably not a fit
Patients with metastatic disease at presentation, those with incomplete electronic records, or those not treated at Tata Memorial Hospital are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This ambispective registration combines a retrospective cohort of patients treated from January 1, 2019 and a prospective cohort enrolled after institutional ethics approval at Tata Memorial Hospital. Clinical, pathological, radiotherapy, toxicity (CTCAE), and quality-of-life data (EORTC QLQ-C30 and VU-34) will be extracted from the electronic medical record and collected prospectively, with planned immunohistochemistry on available tissue blocks. The retrospective arm requests a waiver of consent and will contribute to primary and selected secondary endpoints, while the prospective arm obtains informed consent for ongoing data and QOL collection. The protocol excludes patients with metastatic disease at presentation and those with incomplete medical records.
Why it matters
Potential benefit: If successful, the registry could clarify relapse patterns and late effects after radiation and help guide follow-up care and the design of future interventional trials.
How similar studies have gone: Structured registries and routine QOL measurement have informed care in other rare cancers, but comparable large-scale, India-specific data for vulvo-vaginal cancers are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients diagnosed with vulvo- vaginal cancer. 2. Patients treated with Radiation+/- chemotherapy+/-surgery from January 1, 2019- December 31, 2023. Exclusion Criteria: 1. Patients with Metastatic disease at the presentation. 2. Incomplete information on the EMR.
Where it's running
-
Tata Memorial Hospital
Mumbai, Maharashtra, India Recruiting
Study contacts
- Study coordinator: Dr. Supriya Chopra
- Email: supriyasastri@gmail.com
- Phone: +022-68735000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Vagina-focused AZU-101 for Vulvovaginal Atrophy in Postmenopausal Women
This study tests whether daily vaginal AZU-101 can help postmenopausal women with vulvovaginal atrophy and related dryness, irritation, and pain during sex.
-
F-GYN injection for vaginal dryness and vaginal/vestibular atrophy
This study tests whether a one-time F-GYN injection can relieve vaginal dryness and related symptoms in adult women with atrophic vaginitis/vestibulovaginal atrophy compared with standard non-hormonal care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.